| Trial ID: | L2948 |
| Source ID: | NCT02109029
|
| Associated Drug: |
Insulin Peglispro
|
| Title: |
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02109029/results
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: Insulin Peglispro|DRUG: Human Insulin
|
| Outcome Measures: |
Primary: Part B: Pharmacokinetics: Steady-State Concentrations in Adipose Tissue Interstitial Fluid (ISF), 16, 20, 24, and 28 hours postdose|Part B: Pharmacokinetics: ISF-to-Serum Concentrations, Absolute concentration of ISF of insulin peglispro and human insulin., 16, 20, 24, and 28 hours postdose |
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2014-04
|
| Completion Date: |
2015-03
|
| Results First Posted: |
2019-03-06
|
| Last Update Posted: |
2019-03-06
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, 8036, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT02109029
|
